HUE037600T2 - Vegyületek és készítmények paraziták által okozott fertõzések kezelésére - Google Patents

Vegyületek és készítmények paraziták által okozott fertõzések kezelésére

Info

Publication number
HUE037600T2
HUE037600T2 HUE13795977A HUE13795977A HUE037600T2 HU E037600 T2 HUE037600 T2 HU E037600T2 HU E13795977 A HUE13795977 A HU E13795977A HU E13795977 A HUE13795977 A HU E13795977A HU E037600 T2 HUE037600 T2 HU E037600T2
Authority
HU
Hungary
Prior art keywords
compositions
compounds
treatment
parasitic diseases
parasitic
Prior art date
Application number
HUE13795977A
Other languages
English (en)
Inventor
Arnab Kumar Chatterjee
Advait Suresh Nagle
Prasuna Paraselli
Ravinder Reddy Kondreddi
Seh Yong Leong
Pranab Kumar Mishra
Robert Joseph Moreau
Jason Thomas Roland
Wei Lin Sandra Sim
Oliver Simon
Liying Jocelyn Tan
Bryan Ks Yeung
Bin Zou
Venkatataiah Bollu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE037600T2 publication Critical patent/HUE037600T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HUE13795977A 2012-11-19 2013-11-18 Vegyületek és készítmények paraziták által okozott fertõzések kezelésére HUE037600T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728018P 2012-11-19 2012-11-19
US201361847860P 2013-07-18 2013-07-18

Publications (1)

Publication Number Publication Date
HUE037600T2 true HUE037600T2 (hu) 2018-09-28

Family

ID=49667630

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13795977A HUE037600T2 (hu) 2012-11-19 2013-11-18 Vegyületek és készítmények paraziták által okozott fertõzések kezelésére

Country Status (19)

Country Link
US (3) US9556169B2 (hu)
EP (1) EP2925757B1 (hu)
JP (1) JP6298472B2 (hu)
CN (1) CN105164124B (hu)
AR (1) AR093532A1 (hu)
CY (1) CY1119727T1 (hu)
DK (1) DK2925757T3 (hu)
ES (1) ES2655030T3 (hu)
HR (1) HRP20171998T1 (hu)
HU (1) HUE037600T2 (hu)
LT (1) LT2925757T (hu)
ME (1) ME03042B (hu)
PL (1) PL2925757T3 (hu)
PT (1) PT2925757T (hu)
RS (1) RS56720B1 (hu)
SI (1) SI2925757T1 (hu)
TW (1) TWI600654B (hu)
UY (1) UY35146A (hu)
WO (1) WO2014078802A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
CN108495853A (zh) 2016-01-21 2018-09-04 诺华股份有限公司 用于治疗隐孢子虫病的化合物和组合物
TWI679197B (zh) * 2016-05-05 2019-12-11 瑞士商伊蘭科動物健康公司 雜芳基-1,2,4-***及雜芳基-***化合物
EP3484886B1 (en) * 2016-07-14 2020-03-04 Hoffmann-La Roche AG 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
EP3526220A1 (en) * 2016-10-13 2019-08-21 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds and method for blocking transmission of malarial parasite
WO2018160845A1 (en) * 2017-03-01 2018-09-07 Anacor Pharmaceuticals, Inc. Novel oxaborole analogs and uses thereof
BR112019019494A2 (pt) * 2017-03-20 2020-04-28 Harvard College compostos e métodos para o tratamento de doenças parasitárias
CN107037148B (zh) * 2017-04-07 2019-11-19 上海药明康德新药开发有限公司 卤泛曲林的高效液相检测方法
JOP20190278A1 (ar) 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
AU2019301510A1 (en) * 2018-07-09 2021-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anthelminthic heterocyclic compounds
GB201811695D0 (en) * 2018-07-17 2018-08-29 Salvensis Compounds for use in the treatment of fascioliasis
EP3941587A1 (en) 2019-03-19 2022-01-26 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
AU2020289459A1 (en) * 2019-06-07 2022-01-06 Elanco Tiergesundheit Ag Bicyclic derivatives for treating endoparasites
CA3183100A1 (en) 2020-05-29 2021-12-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anthelmintic heterocyclic compounds
WO2023275590A1 (en) 2021-06-29 2023-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Detection of phosphoinositides in blood cells as a biomarker for alpha synuclein associated pathologies and a method of treatment of parkinson's disease and the related neurodegenerations
WO2023057394A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
CA3181279A1 (en) * 2022-03-24 2023-09-24 Bloom Energy Corporation Fuel cell stack assembly including heat sink inserts
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505524A (ja) 1995-05-01 1999-05-21 藤沢薬品工業株式会社 イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途
EP0915880B1 (en) 1996-07-24 2007-10-10 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
CA2295239A1 (en) 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
JP2001139575A (ja) 1999-11-15 2001-05-22 Fujisawa Pharmaceut Co Ltd 新規ピラゾロピリジン誘導体
GB0002312D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
GB0002336D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
ATE414079T1 (de) * 2000-03-01 2008-11-15 Janssen Pharmaceutica Nv 2,4-disubstituierte thiazolyl derivate
JP2003531906A (ja) 2000-04-28 2003-10-28 グラクソ グループ リミテッド ピラゾロピリジン誘導体の製造方法
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP1382603B1 (en) 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
AUPR916301A0 (en) 2001-11-29 2001-12-20 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
ATE370139T1 (de) 2002-09-17 2007-09-15 Lilly Co Eli Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7488745B2 (en) * 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
RU2007105685A (ru) * 2004-07-16 2008-08-27 Шеринг Корпорейшн (US) Производные гидантонина для лечения воспалительных заболеваний
BRPI0514094A (pt) 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
JP2008516962A (ja) 2004-10-15 2008-05-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管傷害を治療する方法
EP1813613B1 (en) 2004-11-08 2012-12-19 Msd K.K. Novel fused imidazole derivative
DE602005014382D1 (de) * 2004-12-21 2009-06-18 Smithkline Beecham Corp 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
JPWO2006070943A1 (ja) 2004-12-28 2008-06-12 武田薬品工業株式会社 縮合イミダゾール化合物およびその用途
US7713975B1 (en) 2005-01-12 2010-05-11 Alcon, Inc. 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP1928237A4 (en) 2005-09-02 2011-03-09 Abbott Lab NEW HETEROCYCLES BASED ON IMIDAZO
KR101289995B1 (ko) 2005-09-27 2013-07-26 시오노기 앤드 컴파니, 리미티드 Ｐｇｄ2 수용체 길항제 활성을 갖는 설폰아마이드 유도체
US20070129364A1 (en) 2005-12-07 2007-06-07 Han-Qing Dong Pyrrolopyridine kinase inhibiting compounds
EP1963316A2 (en) 2005-12-08 2008-09-03 Novartis AG Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
WO2007086080A2 (en) 2006-01-30 2007-08-02 Glenmark Pharmaceuticals Limited NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2007100775A2 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
EP2038279A2 (en) 2006-06-06 2009-03-25 Avigen, Inc. Substituted pyrazolo [1,5- alpha] pyridine compounds and their methods of use
DE102006029447A1 (de) 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
EP1873157A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
EP2063962A2 (en) 2006-09-07 2009-06-03 Biogen Idec MA Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
EP2062048A4 (en) 2006-09-12 2009-12-02 Gen Hospital Corp METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE CELL SIGNALING AND METHODS EMPLOYING SUCH COMPOUNDS
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
CN101600718B (zh) 2006-11-06 2013-07-03 特雷罗药物股份有限公司 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途
WO2008072682A1 (ja) 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
JP5442448B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物
WO2008094737A2 (en) 2007-01-26 2008-08-07 Irm Llc Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
AU2008266856A1 (en) 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of PFKFB3 inhibitors with anti-neoplastic activities
CA2692653A1 (en) 2007-07-11 2009-01-15 Auckland Uniservices Limited Pyrazolo[1,5-.alpha.]pyridines and their use in cancer therapy
MY154668A (en) 2007-07-19 2015-07-15 Lundbeck & Co As H 5-membered heterocyclic amides and related compounds
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
AU2009218459A1 (en) 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-B] pyridazine derivatives for the treatment of C-Met tyrosine kinase mediated disease
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
EP2300469B1 (en) 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
JP2009298710A (ja) 2008-06-11 2009-12-24 Daiichi Sankyo Co Ltd イミダゾ［１，２−ｂ］ピリダジン誘導体含有医薬組成物
EP2942392B1 (en) 2008-06-30 2018-10-03 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
WO2010017046A1 (en) 2008-08-05 2010-02-11 Merck & Co., Inc. Pyrazolo[1,5-a]pyridines as mark inhibitors
WO2010017047A1 (en) 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
ES2710701T3 (es) * 2008-09-24 2019-04-26 Basf Se Compuestos de pirazol para el control de plagas de invertebrados
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
DK2376490T3 (da) 2008-12-04 2013-04-15 Proximagen Ltd Imidazopyridinforbindelser
WO2010074586A1 (en) 2008-12-23 2010-07-01 Pathway Therapeutics Limited Pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine derivatives and their use in cancer therapy
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
WO2010108074A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Inhibitors of pi3 kinase
WO2010108187A2 (en) 2009-03-20 2010-09-23 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
US8927545B2 (en) 2009-03-30 2015-01-06 Duke University Inhibiting Eph B-3 kinase
WO2010118207A1 (en) 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
TWI421252B (zh) * 2009-07-09 2014-01-01 Irm Llc 用於治療寄生蟲疾病之化合物及組合物
RU2421455C2 (ru) 2009-07-14 2011-06-20 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" СПОСОБ ПОЛУЧЕНИЯ МЕТИЛ 7-АРИЛКАРБАМОИЛ-6-БЕНЗОИЛ-2-МЕТИЛ-3-ФЕНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИН-5-КАРБОКСИЛАТОВ
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
TW201113286A (en) 2009-09-03 2011-04-16 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
EP2480548A4 (en) 2009-09-23 2013-02-20 Panmira Pharmaceuticals Llc INDOLIZIN 5-LIPOXYGENASE INHIBITORS
GB201002911D0 (en) 2010-02-19 2010-04-07 Medical Res Council Compound
EP2920177A1 (en) 2012-11-19 2015-09-23 Novartis AG Compounds and compositions for the treatment of parasitic diseases

Also Published As

Publication number Publication date
US20150344471A1 (en) 2015-12-03
TW201429967A (zh) 2014-08-01
PT2925757T (pt) 2018-01-09
TWI600654B (zh) 2017-10-01
US9926314B2 (en) 2018-03-27
US20160333012A1 (en) 2016-11-17
DK2925757T3 (en) 2018-01-15
LT2925757T (lt) 2017-12-27
ES2655030T3 (es) 2018-02-16
HRP20171998T1 (hr) 2018-02-09
CN105164124B (zh) 2017-03-15
CY1119727T1 (el) 2018-06-27
JP2016505529A (ja) 2016-02-25
EP2925757A1 (en) 2015-10-07
SI2925757T1 (en) 2018-01-31
RS56720B1 (sr) 2018-03-30
UY35146A (es) 2014-06-30
US9556169B2 (en) 2017-01-31
CN105164124A (zh) 2015-12-16
WO2014078802A1 (en) 2014-05-22
PL2925757T3 (pl) 2018-06-29
US20180230145A1 (en) 2018-08-16
EP2925757B1 (en) 2017-10-04
JP6298472B2 (ja) 2018-03-20
ME03042B (me) 2018-10-20
AR093532A1 (es) 2015-06-10

Similar Documents

Publication Publication Date Title
HUE037600T2 (hu) Vegyületek és készítmények paraziták által okozott fertõzések kezelésére
IL241264A0 (en) Compounds and compositions for the treatment of parasitic diseases
HK1212632A1 (zh) 用於治療 介導的疾病的藥物組合物
HUE041553T2 (hu) Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
HK1213798A1 (zh) 治療性化合物和組合物
EP2872151A4 (en) ACELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
EP2827856A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISEASES
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
EP2773342A4 (en) COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES
HK1198909A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
HK1205502A1 (en) Compounds for the treatment of mtor pathway related diseases mtor
HK1215794A1 (zh) 用於治療疾病的同種異體自噬體富集組合物
ZA201408055B (en) Compositions and methods for the treatment of local pain
IL238592B (en) Compounds for the treatment of liver diseases
SG11201404649UA (en) Novel compounds for the treatment of dyslipidemia and related diseases
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases
HUP1100290A2 (en) Combination compositions for the treatment of proliferative diseases
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
SI2812351T1 (sl) Farmacevtski sestavek za zdravljenje multiple skleroze
HK1157189A1 (en) Pharmaceutical composition for the treatment of tumor diseases
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds